SRC and neoplasm: The folic acid treatment induces the activation of the folate receptor alpha (FRα)/SRC/ERK1/2/NFκB signaling pathway, which upregulates TP53 and suppresses cell proliferation and tumor growth in vivo and in vitro, by upregulating the levels of CDKN1A and CDKN1B [205].